AEON Biopharma (AEON) Stock Analysis

What AEON Biopharma does

AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.

Key metrics

ETFs linked to AEON

Broad-market and Healthcare sector ETFs an investor holding AEON Biopharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how AEON fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for AEON Biopharma?

AEON Biopharma trades under the ticker AEON on AMEX.

Which exchange is AEON listed on?

AEON is listed on AMEX.

What sector does AEON Biopharma operate in?

AEON Biopharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze AEON in a portfolio?

PortView shows AEON's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.